VTRO (Vitro Biopharma) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Vitro Biopharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vitro Biopharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

VTRO vs : Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vitro Biopharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitro Biopharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's Margin of Safety % (DCF Earnings Based) falls into.


Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.